We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
16 Oct 2026 - Baar, Switzerland, 16 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive interim […]
Read moreProvisional interim result of the public tender offer of Samsung Biologics Co., Ltd.
13 Oct 2026 - Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional interim […]
Read morePolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
2 Oct 2026 - Baar, 2 October 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published the invitation to its extraordinary general […]
Read moreSamsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG
31 Aug 2026 - Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a […]
Read morePolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin
13 Aug 2026 - Baar, 13 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated […]
Read moreSamsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
20 Jul 2026 - Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to […]
Read morePolyPeptide Group AG takes note of market rumors and speculation
14 Apr 2026 - Baar, 14 April 2026 – PolyPeptide Group AG (SIX: PPGN) (“PolyPeptide” or the “Company”), a specialized global CDMO for peptide-based active pharmaceutical ingredients, takes note of […]
Read morePolyPeptide announces results of the annual General Meeting 2026
8 Apr 2026 - Baar, 8 April 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read morePolyPeptide strengthens financing structure through expansion of existing credit facility
19 Mar 2026 - Baar, 19 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the strengthening of its financing structure through the expansion of its existing credit facility. PolyPeptide has expanded its existing […]
Read more